Congenital prekallikrein deficiency

Expert Review of Hematology

Volumn 3, Issue 6, 2010, Pages 685-695

  Girolami, Antonio ^a   Scarparo, Pamela ^a   Candeo, Nicole ^a   Lombardi, Anna Maria ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

bradikinin; contact phase of blood coagulation; kallikrein; prekallikrein

Indexed keywords

BLOOD CLOTTING FACTOR 12A; BRADYKININ; COUMARIN; HEPARIN; HIGH MOLECULAR WEIGHT KININOGEN; LOW MOLECULAR WEIGHT HEPARIN; PREKALLIKREIN; PROUROKINASE; UROKINASE;

AUTOSOMAL RECESSIVE INHERITANCE; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING FACTOR 12 DEFICIENCY; BLOOD CLOTTING FACTOR DEFICIENCY; BLOOD VESSEL PERMEABILITY; BRAIN ISCHEMIA; CHROMOSOME 4; CLINICAL FEATURE; CONGENITAL PREKALLIKREIN DEFICIENCY; DIFFERENTIAL DIAGNOSIS; DISULFIDE BOND; ENZYME ACTIVATION; EXON; EXTRACORPOREAL CIRCULATION; FIBRINOLYSIS; GENE DUPLICATION; GENETIC ASSOCIATION; GENOTYPE; HEART INFARCTION; HEAVY CHAIN; HUMAN; INCUBATION TIME; INFLAMMATION; INTRON; LABORATORY DIAGNOSIS; LIGHT CHAIN; MOLECULAR BIOLOGY; PARTIAL THROMBOPLASTIN TIME; PHENOTYPE; PLASMA TRANSFUSION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; PROTHROMBIN TIME; REVIEW; THROMBIN TIME; THROMBOSIS; VASODILATATION; VENOUS THROMBOEMBOLISM;

BLOOD COAGULATION DISORDERS; HUMANS; PREKALLIKREIN; PREVALENCE; PROGNOSIS;

EID: 78649511592     PISSN: 17474086     EISSN: None     Source Type: Journal    
DOI: 10.1586/ehm.10.69     Document Type: Review

References (80)

1. Colman RW. Contact activation (kallikrein-kinin) pathway: Multiple physiologic and pathopysiologic activities. In: Hemostasis and Thrombosis (5th Edition). Colman RW, Marder VJ, Clowes AW, George J, Goldhaber S (Eds). Lippincott Williams and Wilkins, PA, USA, 107-130 (2006). Excellent updated overview of the contact phase of blood coagulation.
2. Joseph K, Kaplan AP. Formation of bradykinin: A major contributor to the innate inflammatory response. Adv. Immunol. 86, 159-208 (2005).
3. Colman RW, Schmaier AH. Contact system: A vascular modulation with anticoagulant, profibrinolytic, antiadhesive and proinflammatory attributes. Blood 90, 3819-3843 (1997).
4. Kitchen CS. The contact system Arch. Pathol. Lab. Med. 126, 1382-1386 (2002).
5. Rosenthal RL, Dreskin OH, Rosenthal N. New hemophilia-like disease caused by deficiency of a third plasma thromboplastin factor. Proc. Soc. Exp. Biol. Med. 82, 171-174 (1953). First report of plasma thromboplastin antecedent deficiency.
6. Schmaier AH, McCrae KR. The plasma kallikrein-kinin system: Its evolution from contact activation. J. Thromb. Haemost. 5, 2323-2329 (2007).
7. Shariat-Madar Z, Mahdi F, Schmaier AH. Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J. Biol. Chem. 277, 17962-17969 (2002). (Pubitemid 34967607)
8. Blat Y, Seiffert D. A renaissance for the contact system in blood coagulation? Thromb. Haemost. 99, 457-460 (2008).
9. Gailani D, Renné T. Intrinsic pathway of coagulation and arterial thrombosis. Arterioscler. Thromb. Vasc. Biol. 27, 2507-2513 (2007).
10. Hathaway WE, Belhasen LP, Hathaway HS. Evidence for a new plasma thromboplastin factor I. Case report, coagulation studies and physicochemical properties. Blood 26, 521-532 (1965). First description of a family with prekallikrein (PK) deficiency.
11. Ratnoff OD, Colopy JE. A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma. J. Clin. Invest. 34, 602-613 (1955). First description of a new clotting disorder involving the contact phase. The long story of Mr Hageman and his factor (F)XII deficiency started here.
12. Colman RW, Bagdasarian A, Talamo RC et al. Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways. J. Clin. Invest. 56, 1650-1662 (1975). One of the first independent reports of kininogen deficiency.
13. Wuepper KD, Miller DR, Lacombe MJ. Deficiency of human plasma kininogen. J. Clin. Invest. 56, 1663-1672 (1975). One of the first independent reports of kininogen deficiency.
14. Hathaway WE, Wuepper KD, Weston WL et al. Clinical and physiologic studies of two siblings with prekallikrein (Fletcher factor) deficiency. Am. J. Med. 60, 654-664 (1976).
15. Hattersley PG, Hayse D. Fletcher factor deficiency: A report of three unrelated cases. Br. J. Haematol. 18, 411-416 (1970).
16. De La Cadena RA. Fletcher factor deficiency in a 9-year-old girl: Mechanisms of the contact pathway of blood coagulation. Am. J. Hematol. 48, 273-277 (1995).
17. Currimbhoy Z, Vinciguerra V, Palakavongs P, Kuslansky P, Degnan TJ. Fletcher factor deficiency and myocardial infarction. Am. J. Clin. Pathol. 65, 970-974 (1976).
18. Acar K, Yagci M, Sucak GT, Haznedar R. Isolated prolonged activated partial thromboplastin time in an asymptomatic patient: Fletcher factor deficiency. Thromb. Res. 118, 765-766 (2006).
19. Asmis LM, Sulzer I, Furlan M, Lämmle B. Prekallikrein deficiency: The characteristic normalization of the severely prolonged aPTT following increased preincubation time is due to autoactivation of factor XII. Thromb. Res. 105, 463-470 (2002).
20. Aznar JA, Espana F, Aznar J, Tascon A, Jimenez C. Fletcher factor deficiency: Report of a new family. Scand. J. Haematol. 21, 94-98 (1978).
21. Lombardi AM, Sartori MT, Cabrio L, Fadin M, Zanon E, Girolami A. Severe prekallikrein (Fletcher factor) deficiency due to a compound heterozygosis (383Trp stop codon and Cys529Tyr). Thromb. Haemost. 90, 1040-1045 (2003). First family with PK deficiency studied by molecular biology techniques and found to be compound heterozygotes.
22. Kolodie L, Poirot P, Foret C. Un cas de déficit en facteur Fletcher. Nouv. Rev. Franc. 22, 89-90 (1980).
23. Kyrle PA, Niessner H, Deutsch E, Lechner K, Korninger C, Mannhalter C. CRM+ severe Fletcher factor deficiency associated with Graves' disease. Haemostasis 14, 302-306 (1984).
24. Hess DC, Krauss JS, Rardin D. Stroke in a young adult with Fletcher trait. South Med. J. 84, 507-508 (1991).
25. Hruby J. Quoted by Raffoux et al. Hum. Genet. 60, 71-73 (1982).
26. Isobe J. [Prekallikrein deficiency (Fletcher trait)]. Ryoikibetsu Shokogun Shirizu. 21, 468-470 (1998).
27. Bouma BN, Kerbiriou DM, Baker J, Griffin JH. Characterization of a variant prekallikrein, prekallikrein Long Beach, from a family with mixed cross-reacting material-positive and cross-reacting material-negative prekallikrein deficiency. J. Clin. Invest. 78, 170-176 (1986).
28. Colla G, Carrea M, Sbaffi A. Fletcher factor deficiency (report of a new case). Ric. Clin. Lab. 13, 443-448 (1983).
29. De Stefano V, Leone G, Teofili L et al. Association of Graves' disease and prekallikrein congenital deficiency in a patient belonging to the first CRM+ prekallikrein-deficient Italian family. Thromb. Res. 60, 397-404 (1990).
30. Joggi J, Stalder M, Knecht H, Hauert J, Bachmann F. Déficience en prékallicréine: À propos de 2 cas. Schweiz Med. Wschr. 120, 1942-1944 (1990).
31. Castaman G, Ruggeri M, Rodeghiero F. A new Italian family with severe prekallikrein deficiency. Desmopressininduced fibrinolysis and coagulation changes in homozygous and heterozygous members. Ric. Clin. Lab. 20, 239-244 (1990).
32. Entes K, LaDuca FM, Tourbaf KD. Fletcher factor deficiency, source of variations of the activated partial thromboplastin time test. Am. J. Clin. Pathol. 75, 626-628 (1981).
33. Eeckhoudt SL, Momeni M, Matta A, Latinne D, Arnout J, Hermans C. Management of prekallikrein deficiency during cardiac surgery. Thromb. Haemost. 103, 866-867 (2010).
34. Dietzel H, Lutze G, Kätzel R, Liebscher K. Präkallikrein- (Fletcher-Faktor-)Defekt als Ursache einer präoperativen APTT-V erlängerung. Med. Klin. (Munich) 98, 587-590 (2003).
35. François D, Trigui N, Leterreux G et al. Severe prekallikrein deficiencies due to homozygous C529Y mutations. Blood Coagul. Fibrinolysis 8, 283-286 (2007).
36. Girolami A, Marun SG, Vettore S et al. A large family from Argentina with prekallicrein deficiency due to a compound heterozygosis (T insertion in intron 7 and Asp558Glu in exon 15): Prekallikrein Cordoba. Am. J. Hematol. 85(5), 363-366 (2010).
37. Harris MG, Exner T, Rickard KA, Kronenberg H. Multiple cerebral thrombosis in Fletcher factor (prekallikrein) deficiency: A case report. Am. J. Hematol. 19, 387-393 (1985).
38. Jones DW, Russell G, Allford SL et al. Severe prekallikrein deficiency associated with homozygosity for an Arg94Stop nonsense mutation. Br. J. Haematol. 127, 220-223 (2004).
39. Katsuda I, Maruyama F, Ezaki K, Sawamura T, Ichihara Y. A new type of plasma prekallikrein deficiency associated with homozygosity for Gly104Arg and Asn124Ser in apple domain 2 of the heavy-chain region. Eur. J. Haematol. 79, 59-68 (2007).
40. Malacrida A, Chantarangkie V, Tripodi A. Carenza di precallicreina e tempo di tromboplastina parziale attivato (aPTT). Riv. Med. Lab. 5, 40-42 (2004).
41. Nagaya S, Morishita E, Takami A et al. An elderly case of congenital prekallikrein deficiency. Nippon Ronen Igakkai Zasshi 46, 348-351 (2009).
42. Odumosu MC, Yoong WC, Fakokunde AF. Fletcher factor deficiency in a woman requiring emergency caesarean section. J. Obstet. Gynaecol. 29, 442 (2009).
43. Pasricha SK, Weiss H, Chen A. Spinal anesthesia in a patient with prekallikrein deficiency. Anesth. Analg. 83, 1325-1326 (1996).
44. Poon MC, Moore MR, Castleberry RP, Lurie A, Huang ST, Lehmeyer J. Severe Fletcher factor (plasma prekallikrein) deficiency with partial deficiency of Hageman factor (factor XII): Report of a case with observation on in vivo and in vitro leukocyte chemotaxis. Am. J. Hematol. 12, 261-270 (1982).
45. Raffoux C, Alexandre P, Perrier P, Briquel ME, Streiff F. HLA typing in a new family with Fletcher factor deficiency. Hum. Genet. 60, 71-73 (1982).
46. Saito H, Goodnough LT, Soria J, Soria C, Aznar J, Espana F. Heterogeneity of human prekallikrein deficiency (Fletcher trait): Evidence that five of 18 cases are positive for cross-reacting material. N. Engl. J. Med. 305, 910-914 (1981). First demonstration of heterogeneity in PK deficiency. First description of cross-reacting material-positive variants.
47. Saade M. Fletcher factor deficiency with mildly prolonged activated PTT. South Med. J. 73, 958 (1980).
48. Shigekiyo T, Fujino O, Kanagawa Y, Matsumoto T. Prekallikrein (PK) Tokushima: PK deficiency caused by a Gly401- >Glu mutation. J. Thromb. Haemost. 1, 1314-1316 (2003).
49. Sollo DG, Saleem A. Prekallikrein (Fletcher factor) deficiency. Ann. Clin. Lab. Sci. 15, 279-285 (1985).
50. Van Veen JJ, Laidlaw S, Swanevelder J et al. Contact factor deficiencies and cardiopulmonary bypass surgery: Detection of the defect and monitoring of heparin. Eur. J. Haematol. 82, 208-212 (2009).
51. Waddell CC, Brown JA, Udden MM. Plasma prekallikrein (Fletcher factor) deficiency in a patient with chronic lymphocytic leukemia. South Med. J. 73, 1653-1655 (1980).
52. Wuillemin WA, Furlan M, von Felten A, Lämmle B. Functional characterization of a variant prekallikrein (PK Zürich). Thromb. Haemost. 70, 427-432 (1993).
53. Oram MP, Mumford AD, Morse C, Underwood S. Management of anticoagulation for coronary artery bypass surgery in a patient with severe prekallikrein deficiency. J. Cardiothorac. Vasc. Anesth. 20, 580-582 (2006).
54. Dasanu CA, Alexandrescu DT. A case of prekallikrein deficiency resulting in severe recurrent mucosal hemorrhage. Am. J. Med. Sci. 338, 429-430 (2009).
55. Maak B, Kochhan L, Heuchel P, Jenderny J. Severe prekallikrein deficiency due to a compound heterozygosis in the KLKB1-gene Hamostaseologie 29, 187-189 (2009).
56. Yu H, Anderson PJ, Freedman BI, Rich SS, Bowden DW. Genomic structure of the human plasma prekallikrein gene, identification of allelic variants, and analysis in end-stage renal disease. Genomics 69, 225-234 (2000).
57. Mandle R, Kaplan AP. Hageman factor substrates Hageman factor substrates. Human plasma prekallikrein: Mechanism of activation by Hageman factor and participation in Hageman factor-dependent fibrinolysis. J. Biol. Chem. 252, 6097-6104 (1977). First purification of PK.
58. Mandle RI, Coleman RW Kaplan AP. Identification of prekallikrein and high-molecular-weight kininogen as a complex in human plasma. Proc. Natl Acad. Sci. 73, 4179-4183 (1976).
59. Scott CF, Colman RW. Function and immunochemistry of prekallikrein-high molecular weight kininogen complex in plasma. J. Clin. Invest. 65, 413-421 (1980).
60. Chung DW, Fujikawa K, McMullen BA, Davie EW. Human plasma prekallikrein, a zymogen to a serine protease that contains four tandem repeats. Biochemistry 25, 2410-2417 (1986).
61. Joseph K, Tholanikunnel BG, Kaplan AP. Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII. Proc. Natl Acad. Sci. 99, 896-900 (2002).
62. Harpel PC, Lewin MF, Kaplan AP. Distribution of plasma kallikrein between C-1 inactivator and a 2-macroglobulin in plasma utilizing a new assay for a 2-macroglobulin-kallikrein complexes. J. Biol. Chem. 260, 4257-4263 (1985).
63. Girolami A, Allemand E, Bertozzi I, Candeo N, Marun S, Girolami B. Thrombotic events in patients with congenital prekallikrein deficiency. A critical evaluation of all reported cases. Acta Haematol. 123, 210-214 (2010).
64. Goodnough LT, Saito H, Ratnoff OD. Thrombosis or myocardial infarction in congenital clotting factor abnormalities and chronic thrombocytopenias: A report of 21 patients and a review of 50 previously reported cases. Medicine (Baltimore) 62, 248-255 (1983). First systematic evaluation of the occurrence of thrombotic events in congenital or acquired bleeding disorders.
65. Zeerleder S, Schloesser M, Redondo M et al. Reevaluation of the incidence of thromboembolic complications in congenital factor XII deficiency - a study on 73 subjects from 14 Swiss families. Thromb. Haemost. 82, 1240-1246 (1999).
66. Girolami A, Randi ML, Gavasso S, Lombardi AM, Spiezia F. The occasional venous thromboses seen in patients with severe (homozygous) FXII deficiency are probably due to associated risk factors: A study of prevalence in 21 patients and review of the literature. J. Thromb. Thrombolysis 17, 139-143 (2004).
67. Girolami A, Simioni P, Scarano L, Girolami B, Zerbinati P. Symptomatic combined homozygous factor XII deficiency and heterozygous factor V Leiden. J. Thromb. Thrombolysis 9, 271-275 (2000). (Pubitemid 30201260)
68. Girolami A, Candeo N, Berti de Marini G, Bonamigo E, Girolami B. Comparative incidence of thrombosis in reported cases of deficiencies of factors of the contact phase of blood coagulation. J. Thromb. Thrombolysis. DOI: 10.1007/s11239-010- 0495-z (2010) (Epub ahead of print).
69. Ratnoff OD, Busse RJ, Sheon RP. The demise of Mr John Hageman. N. Engl. J. Med. 279, 760-761 (1968).
70. Slight RD, Buell R, Nzewi OC, McClelland DB, Mankad PS. A comparison of activated coagulation time-based techniques for anticoagulation during cardiac surgery with cardiopulmonary bypass. J. Cardiothorac. Vasc. Anesth. 22, 47-52 (2008).
71. Girolami A, Candeo N, Vettore S, Lombardi AM, Girolami B. The clinical significance of the lack of arterial or venous thrombosis in patients with congenital prothrombin or FX deficiency. J. Thromb. Thrombolysis. 14, 177-181 (2009).
72. Cankovic L, Steenwyk BL, McGiffin DC, Nielsen VG. Practical approach to anticoagulation for cardiopulmonary bypass in the patient with congenital prolonged activated partial thromboplastin time. Blood Coagul. Fibrinolysis. 19, 725-726 (2008).
73. Girolami A, Ruzzon E, Tezza F, Scandellari R, Vettore S, Girolami B. Arterial and venous thrombosis in rare congenital bleeding disorders: A critical review. Haemophilia 12, 345-351 (2006). First systematic analysis of thrombotic events in patients with rare bleeding disorders. Demonstration that only FII or FX deficiency seem to protect fully from thrombosis.
74. Gallimore MJ. Chromogenic peptide substrate assays for determining components of the plasma kallikrein system. Scand. J. Clin. Lab. Invest. Suppl. 178, 127-132 (1985).
75. Girolami A, Scandellari R, Zanon E, Sartori R, Girolami B. Non-catheter associated venous thrombosis in hemophilia A and B. A critical review of all reported cases. J. Thromb. Thrombolysis 21, 279-284 (2006).
76. Girolami A, Tezza F, Scapin M, Vettore S, Casonato A. Arterial and venous thrombosis in patients with von Willebrand's disease: A critical review of the literature. J. Thromb. Thrombolysis 21, 175-178 (2006).
77. Endler G, Marsik C, Jilma B, Schickbauer T, Quehenberger P, Mannhalter C. Evidence of a U-shaped association between factor XII activity and overall survival. Thromb. Haemost. 5, 1143-1148 (2007).
78. Maas C, Govers-Riemslag JW, Bouma B et al. Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation. J. Clin. Invest. 118, 3208-3218 (2008). Suggests the possibility of autoactivation of FXII upon exposure to misfolded proteins - ex-amyloid - with consequent kallikrein formation but no activation of coagulation.
79. Schmaier AH. The elusive physiologic role of factor XII. J. Clin. Invest. 118, 3006-3009 (2008). Offers a new perspective on the physiological role of FXII.
80. Müller F, Renné T. Novel roles for factor XII-driven plasma contact activation system. Curr. Opin. Hematol. 15, 516-521 (2008).